This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results
by Zacks Equity Research
The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.
Exactech (EXAC) Gets Acquired by TPG Capital, Goes Private
by Zacks Equity Research
TPG Capital acquires Exactech (EXAC) with a view to cash in on its resources and gain a foothold in the orthopedics market.
Company News For Dec 5, 2017
by Zacks Equity Research
Companies In The News are: AET,BGC,CVS,FMI,EXAC
Exactech (EXAC) Truliant Knee System Receives IDEA Award
by Zacks Equity Research
Exactech (EXAC) has been leveraging on its Knee business. The Truliant Knee System is a notable platform in the Knee space, which offers an advanced approach to total knee replacement surgeries.
Exactech Boosts Knee System Portfolio, Launches New App
by Zacks Equity Research
Exactech, Inc.(EXAC) took a step towards it's goal of providing an all-inclusive range of knee replacement systems with the launch of ExactechGPS TKA PLUS.
Exactech (EXAC) Launches Application for Knee Replacement
by Zacks Equity Research
Gainesville, FL-based Exactech Inc. (EXAC) recently announced the launch of a new software application christened ExactechGPS TKA PLUS.
Exactech (EXAC) Gets FDA Approval for ExactechGPS Application
by Zacks Equity Research
Exactech Inc. (EXAC) recently announced that it has received clearance from the U.S. Food and Drug Administration to market its proprietary ExactechGPS Shoulder Application in US.
4 Medical Instrument Makers to Save Your Portfolio
by Jeremy Mullin
Technology in the medical world is leading these companies to breakthrough devices, which save and extend lives.